Welcome to our dedicated page for CRYO CELL INTERNATIONAL SEC filings (Ticker: CCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cryo-Cell International filings document material events, governance matters, financing arrangements and exchange-listing compliance for a cord blood banking and cryogenic storage company. Recent 8-K reports cover NYSE American continued-listing standards, dividend determinations, annual meeting timing, and Regulation FD disclosures tied to company announcements.
The filing record also includes definitive proxy materials for director elections, auditor ratification, executive compensation voting and stockholder meeting procedures. Financing disclosures describe amendments to the company’s Susser Bank credit agreement, including revolving credit and term loan arrangements, subsidiary guarantor provisions involving Celle Corp., maturity terms, interest-rate mechanics and related security documents.
Cryo-Cell International, Inc. (CCEL) announced the schedule for its 2026 Annual Meeting of Stockholders. The Board of Directors set October 27, 2026 as the meeting date and September 21, 2026 as the record date for determining which stockholders are entitled to receive notice of and vote at the meeting.
The company also noted that, under its Bylaws, the deadlines for stockholders to submit proposals of business or director nominations for consideration at the 2026 Annual Meeting were both July 27, 2026. These deadlines have already passed.
Cryo-Cell International Inc. Chairman and Co-CEO David Portnoy restructured his holdings on August 5, 2026 by transferring 600,191 common shares to the David Portnoy Irrevocable 2026 Trust Agreement. The trust borrowed $800,000.26, used to satisfy Portnoy’s indebtedness, and he personally guaranteed repayment. The reported $1.3329 per share value is simply the loan amount divided by the transferred shares and not their fair market value. Portnoy is not a beneficiary of the trust, cannot revoke it and, for Section 16 purposes, disclaims beneficial ownership of its shares except for any pecuniary interest. After the transfer he directly holds 247,438 shares, has several indirect positions, and retains stock options including 280,000 underlying shares at $12.27 and 150,000 underlying shares at $3.89 per share.
Camac Fund and related entities filed an amended Schedule 13D reporting a significant stake in Cryo-Cell International. Camac Fund beneficially owns 551,081 shares of Cryo-Cell common stock, representing approximately 6.8% of the 8,055,150 shares outstanding as of April 14, 2026. The fund acquired these shares for an aggregate purchase price of about $1,807,998 using working capital, which may include margin loans.
The reporting group, including Camac Partners, Camac Capital and manager Eric Shahinian, states it bought the shares because it viewed them as undervalued and an attractive investment. They indicate they may increase or decrease their position and may engage with Cryo-Cell’s management and board on topics such as board composition, corporate governance, spending levels, asset monetization and returning capital to shareholders.
Cryo-Cell International VP Finance and CFO Jill M. Taymans exercised stock options to acquire 7,500 shares of Common Stock on May 28, 2026 at $3.10 per share. Following this exercise, she directly holds 52,896 Common Stock shares.
She also retains multiple outstanding stock option awards on Common Stock with exercise prices ranging from $3.54 to $8.00 per share and expiration dates between 2027 and 2031, covering several tranches of 7,000 to 20,000 underlying shares each, subject to stated vesting and performance conditions.
Cryo-Cell International, Inc. announced that NYSE Regulation has accepted its plan to regain compliance with the continued listing standards of NYSE American. The exchange granted a plan period through September 9, 2027, during which Cryo-Cell’s common stock will continue to trade on NYSE American.
The company was previously notified it was not in compliance with Section 1003(a) of the NYSE American Company Guide due to a stockholders’ deficit as of November 30, 2025 and net losses in two of its three most recent fiscal years. The listing remains subject to ongoing review, and NYSE American may initiate delisting proceedings if Cryo-Cell does not regain compliance or fails to make sufficient progress under the plan.
Camac Fund and related entities disclosed a 5.3% stake in Cryo-Cell International, Inc. common stock on a Schedule 13D. They report beneficial ownership of 430,900 shares, acquired for approximately $1,354,672, based on 8,055,150 shares outstanding as stated in Cryo-Cell’s Form 10-K for the period ended November 30, 2026.
The position was purchased with working capital and is held through Camac Fund, with Camac Partners, Camac Capital and Eric Shahinian sharing voting and dispositive power. The investors state they believed the shares were undervalued and may increase or decrease their holdings or use hedging strategies over time.
The group describes itself as active, indicating plans to periodically review the investment and potentially engage with Cryo-Cell’s management, Board, other stockholders and third parties on topics such as Board composition and corporate governance, spending levels, monetization of company assets and return of capital to shareholders.
Cryo-Cell International, Inc. has received a notice from NYSE American that it is not in compliance with continued listing standards under Section 1003(a) of the NYSE American Company Guide. The exchange cited a stockholders’ deficit as of November 30, 2025 and net losses in two of the three most recent fiscal years.
The company’s common stock will continue trading on NYSE American under the symbol CCEL while it prepares and submits a compliance plan, which it intends to file by April 8, 2026. If the plan is not accepted or compliance is not regained within any allowed period, NYSE American may begin delisting proceedings.
Cryo-Cell International, Inc. provides cord blood and cord tissue processing and storage, manufactures the PrepaCyte CB processing system, and operates both private and public cord blood banking, including units listed through the National Marrow Donor Program.
The company highlights its cGMP/cGTP-compliant facilities, AABB and FACT accreditations, over 250,000 specimens stored with global affiliates, and a new Durham, North Carolina facility that also supports the ExtraVault third‑party cold storage service for biopharma customers.
A central theme is the now-contested Duke License Agreement. Cryo-Cell alleges Duke fraudulently induced and then breached the agreement, has filed an arbitration demand claiming damages it believes exceed $100 million, and has recorded a full impairment of the related asset. Duke has issued a notice of termination effective May 17, 2025 and asserted counterclaims for breach and indemnity, with a final arbitration hearing scheduled for April 2026.
Until this dispute is resolved, expansion into infusion clinics and biopharmaceutical manufacturing, the opening of the Cryo-Cell Institute for Cellular Therapies, and the proposed spin-off of its Celle Corp. subsidiary are all on hold, and the company cautions that the arbitration outcome could materially affect its business and financial position.